Glucocorticoids: Action and new therapeutic insights in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 19, Issue 3, 2007, Pages 233-237

  Kirwan, John ^a   Power, Lynsey ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Arthritis; Glucocorticoids; Therapeutics

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; AL 438; ANNEXIN; DIPYRIDAMOLE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; LIPOSOME; METHOTREXATE; NCX 1015; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCALCIN; OSTEOPROTEGERIN; PAROXETINE; PREDNISOLONE; STEROID; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; CIRCADIAN RHYTHM; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; GROOMING; HUMAN; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; OSSIFICATION; PAW EDEMA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SCORING SYSTEM; SKIN INFLAMMATION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TRANSCRIPTION INITIATION; X RAY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, GLUCOCORTICOID;

EID: 34247168097     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3280d6471a     Document Type: Review

References (26)

1. Kirwan JR. The effect of glucocorticoids of joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333:142-146.
2. Morrison E, Capell H. Corticosteroids in the management of rheumatoid arthritis. Rheumatology 1996; 35:2-4.
3. Jacobs JWG, van Everdingen AA, Verstappen SMM, Bijlsma JWJ. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006; 54:1422-1428. This long term follow up study demonstrates that prednisolone given in early rheumatoid arthritis has a continuing suppressive effect on X-ray progression several years after the glucocorticoids have been withdrawn.
4. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:3371-3380.
5. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005; 52:3360-3370.
6. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. [see comment]. Arthritis Rheum 2005; 52:3381-3390.
7. Kirwan JR, Bijlsma JWJ, Boers M, Shea B. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007; 1:CD006356.
8. Landewe RBM, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46:347-356.
9. Hauge berg G, Strand A, Kvien T, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis. Arch Intern Med 2005; 165:1293-1297.
10. Georgiadis AN, Papavasiliou EC, Evangelia SL, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther 2006; 8:R82.
11. Buttgereit F, Doering G, Schaeffler A, et al. New modified-release (MR) tablet formulation of prednisone significantly reduces duration of morning stiffness compared to standard prednisone in subjects with rheumatoid arthritis (RA). In: Program book supplement of American College of Rheumatology 2006 Annual Scientific Meeting; 10-15 November 2006; Washington, DC. (488)L8, p. 12.
12. Price R, Manivasakam P, Robinson E, et al. Molecular insight into steroid dissociation of CRx-102, a clinically active immunomodulatory agent. Arthritis Rheum 2006; 54 (Suppl 9):S592.
13. Bartholome B, Spies CM, Gaber T, et al. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J 2004; 18:70-80.
14. Schacke H, Schottelius A, Docke W-D, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 2004; 101:227-232.
15. Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 2003; 17:860-869.
16. Betageri R, Zhang Y, Zindell RM, et al. Trifluoromethyl group as a pharmacophore: Effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand. Bioorg Med Chem Lett 2005; 15:4761-4769.
17. De Bosscher K, Berghe WV, Beck IME, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A 2005; 102:15827-15832.
18. Thompson CF, Quraishi N, Ali A, et al. Novel heterocyclic glucocorticoids: In vitro profile and in vivo efficacy. Bioorg Med Chem Lett 2005; 15:2163-2167.
19. Barker M, Clackers M, Copley R, et al. Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series. J Med Chem 2006; 49:4216-4231. Important demonstration using several in-vitro techniques that the different actions of the glucocorticoid receptor can be separated from each other by stimulation with nonsteroidal molecules which act as ligands for the glucocorticoid receptor.
20. Kvien TK, Slatkowsky-Christensen B, Fjeld E, et al. Efficacy and safety of a novel syncretic drug candidate - CRX-102 - in hand osteoarthritis. Ann Rheum Dis 2006; 65 (Suppl II):236.
21. Price R, Manivasakam P, Slavonic M, et al. CRx-139: a novel syncretic drug candidate targeted for the treatment of immuno-inflammatory disease. Arthritis Rheum 2006; 54 (Suppl 9):S409.
22. Baraldi PG, Romagnoli R, Del Carmen Nunez M, et al. Synthesis of nitro esters of prednisolone, new compounds combining pharmacological properties of both glucocorticoids and nitric oxide. J Med Chem 2004; 47:711-719.
23. Kirwan JR, Hallgren R, Mielants H, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004; 63:688-695.
24. Koning GA, Schiffelers RM, Wauben MHM, et al. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum 2006; 54:1198-1208. An excellent demonstration of localization of glucocorticoid delivery and its importance for human trials.
25. Perry MG, Richards LJ, Harbuz MS, et al. IL-6 in Rheumatoid arthritis varies overnight with mean morning pead before mean cortisol, TNFα shows no overnight change. Rheumatology 2006; 45 (Supplement 1):i38.
26. Pretorius E, Wallner B, Marx J. Cortisol resistance in conditions such as asthma and the involvement of 11beta-HSD: a hypothesis. Horm Metab Res 2006; 38:368-376.